GlycoEra
PrivateLast Round
Series B
May 27, 2025
Total Funding Raised
$179M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
GlycoEra is a biotechnology company that develops innovative biologics and protein degraders to treat inflammatory, autoimmune, and immune-oncology conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
GlycoEra Comparables
Compare GlycoEra with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Lycia Therapeutics | 83% | |
| Avilar Therapeutics | 83% | |
| Biohaven Ltd. | 78% |
GlycoEra Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | May 27, 2025 | ||||
| Series A Extension | Jan 5, 2024 | ||||
| Series A | Nov 5, 2021 |
Key People
Founding team and executive leadership
GlycoEra Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Agent Capital | Series B |
| Roche Venture Fund | Series B, Series A |
| Sixty Degree Capital | Series B |
| MP Healthcare Venture Management | Series B |
| 5AM Ventures | Series B, Series A Extension, Series A |
| Catalio Capital Management | Series B |
| Roche Venture Fund | Series A Extension, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2026
Monthly visitors grew 109% MoM, from 1.7K to 3.5K.
- Jan 8, 2026
Petra Duda, M.D., Ph.D. appointed as new CMO.
Recent news
Latest coverage and updates
- hiresSep 17, 2026
GlycoEra, Inc. hired Andrea Matthews as chief business officer on Sep 17th '26.
GlycoEra Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about GlycoEra's valuation, stock price, and market status.
Is GlycoEra a public or private company?
GlycoEra is a private company.
What is the current stock price of GlycoEra?
GlycoEra is a private company with no public stock price. No recent secondary market data is available.
How much is GlycoEra worth (valuation)?
Valuation information for GlycoEra is not publicly available.
Can I buy GlycoEra stock?
GlycoEra shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was GlycoEra's last funding round?
GlycoEra's most recent funding round was Series B on May 27, 2025.
Who are the main investors in GlycoEra?
Key investors in GlycoEra include 5AM Ventures, Roche Venture Fund, Novo Holdings, Sofinnova Partners.
Will GlycoEra IPO soon?
No public IPO plans have been announced for GlycoEra.
How can I track GlycoEra secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor GlycoEra's secondary market activity and sign up for updates.